Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deproteinized bovine bone (DBB), most commonly known by the brand name **Bio-Oss**, is a xenogenic bone substitute material used extensively in dental and maxillofacial surgery for bone regeneration. Manufactured by **Geistlich Pharma**, it is produced by removing all organic components from bovine bone through a high-temperature treatment process, leaving a porous mineral scaffold composed of natural hydroxyapatite. This scaffold is chemically and structurally similar to human bone, providing an osteoconductive environment that supports the attachment and proliferation of osteogenic cells and the ingrowth of new bone tissue. While it lacks intrinsic osteoinductive or osteogenic properties, it is highly effective for maintaining volume in alveolar ridge preservation, sinus floor elevation, and periodontal defect repair. It is often used in combination with barrier membranes (like Bio-Gide) or growth factors to enhance clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deproteinized bovine bone.